A Long-term Safety Follow-up Study of Patients Having Received Infusions of HepaStem
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Liver disorders
- Focus Adverse reactions; First in man
- Acronyms SAF 001
- Sponsors Promethera Biosciences
- 30 Mar 2017 This trial has been completed in Portugal.
- 02 Oct 2014 Planned End Date changed from 1 Mar 2017 to 1 Oct 2018 as reported by ClinicalTrials.gov record.
- 02 Oct 2014 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2018 as reported by ClinicalTrials.gov record.